Quarterly report · Q2
9987.TEDINET S100PLBR
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.14T | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥2.24T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.10T | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥14.9bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥7.1bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥16.7bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.8bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥16.5bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥13.4bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥10.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥10.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥9.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥1.19T | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥1.14T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.16T | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥764.4bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥723.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥429.1bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥418.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥422.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥132.9bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥141.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥155.8bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥159.0bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥28.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥9.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥37.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥123.36 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.86 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.75 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥108.92 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.9% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥107.1bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥19.9bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥87.2bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥930m |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥43.2bn |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥43.2bn |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5m |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥644m |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.09T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.07T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥25.1bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥12.1bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥22.7bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥17.2bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.27T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.14T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥129.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥85.3bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥19.4bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥65.9bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥44.0bn |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥13m |
| jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.06T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.03T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥25.8bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥21.9bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥15.9bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥1.21T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥1.10T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥107.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥7.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 501
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 88000000 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 11595000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1318 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 4189000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0476 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 3683000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0418 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 3256000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0370 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 3091000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0351 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 2404000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0273 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 2340000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0266 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 2265000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0257 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 2079000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0236 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 1943000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0220 | |
| Number of shares held | CurrentQuarterInstant | 36847000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.4188 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 15370200 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 87764100 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 877641 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 209783 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 103344083 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 877641 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 15370200 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 15370200 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.1487 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 15370200 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 15370200 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.1487 | |
| Cash and deposits | Prior1YearInstant | 141377000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 132941000000 | JPY |
| Notes and accounts receivable trade | Prior1YearInstant | 518408000000 | JPY |
| Notes and accounts receivable trade | CurrentQuarterInstant | 539773000000 | JPY |
| Short term investment securities | Prior1YearInstant | 60086000000 | JPY |
| Short term investment securities | CurrentQuarterInstant | 82398000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 130584000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 136167000000 | JPY |
| Work in process | Prior1YearInstant | 2465000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |